In the patient-only intervention group, the rate of skin self-examination and physician skin examination increased from 15.8% at baseline to 47.5% at 12 months; in the group that also had outreach to ...

During a live Case-Based Roundtable event, Brea Lipe, MD, and participants discussed treatment options for an older patient who already received multiple bispecific antibodies for multiple myeloma.

A City of Hope study found success in promoting skin cancer screening to transplant survivors, Dr Saro Armenian explains.

SOHO-01 used blinded independent central review per RECIST v1.1 and enrolled locally advanced/metastatic nonsquamous NSCLC ...

Sex-stratified outputs showed similar overdiagnosis proportions but higher absolute rates in women, yielding an estimated 443 ...

Geoffrey Y. Ku, MD, gastrointestinal medical oncologist and cellular therapist, MSK, discusses the significance of the CLDN18.2-directed CAR T-cell therapy satricabtagene autoleucel (satri-cel) for ...

An interim analysis of a phase 2b trial (NCT04974008) showed a 3-year OS rate of 71.2% among OST-HER2–treated patients compared with 45.8% in a comparable combined historical control group (90% CI, 11 ...

Martin Dietrich, MD, PhD, says the first move at progression is to extend frontline therapy rather than abandon it, looking ...

Wade Iams, MD, says progression-free survival (PFS) drives his frontline choice, since median overall survival remains years ...

Comprehensive modeling incorporating reproductive, lifestyle, neighborhood, clinical, and treatment variables did not ...

Dr Shubham Pant outlines what's next for daraxonrasib in pancreatic cancer, including the RASolute 303 and RASolute 304 ...

Few areas of blood cancer treatment have evolved as rapidly as T-cell–based immunotherapy. Chimeric antigen receptor (CAR) ...